ClinicalTrials.gg
TerminatedNCT04571749HATRICC-USUpdated Oct 13, 2026

Handoffs and Transitions in Critical Care - Understanding Scalability

An interventional study of Customized handoff in Patient Handoff, Healthcare Team and Communication, sponsored by University of Pennsylvania. Terminated at 5 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by University of Pennsylvania · Not applicable, Interventional, and Health services research

How we know

Why this study was terminated
PI Lane-Fall moved to a new institution. The original funding period ended and the grant was closed by the original institution before it was moved. We are working on reestablishing the IRB at the new institution to finish analysis procedures.
Updated Oct 13, 2026Now TerminatedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4,000
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Communication by University of Pennsylvania — 5 open to participants now, 6 under way, none of them phase 3. Communication · University of Pennsylvania.

Enrollment
2nd of 15
4,000 · median 523
Started
2021
the only one that year
No phase
15 of 15
5 open now
Registered
8th of 15
by date

Among the 15 studies in Communication by University of Pennsylvania, this one is the 2nd largest by enrollment, is the only one that started in 2021, is one of 15 with no phase, and was the 8th registered.

Communication

720 studies on the registry are indexed under Communication; 160 are open to participants now.

Browse Communication studies →

Open to participants now

5 of the 15 studies in Communication by University of Pennsylvania are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 88 Communication studies recruiting now, 53 (60%) set no upper age limit and 28 (32%) stop at 75 or younger; 32 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Communication by University of Pennsylvania, or all of them as a file.
02

Study summary

The investigators will leverage implementation science and engineering to adapt, implement, and rigorously evaluate tailored postoperative handoff protocols and implementation strategies. In doing so, the investigators will develop a vital understanding of the factors needed for successful and sustained use of evidence-based interventions in acute care. This knowledge will inform approaches to bridge the evidence-to-practice gap that prevents effective interventions from realizing the promise of improved patient outcomes in acute care settings.

Read the detailed description

Surgical patients who require post-surgical critical care are usually transferred from the operating room (OR) to the intensive care unit (ICU) for ongoing care. The process of transferring the patient from the OR to the ICU is called a "handoff." Handoffs involve the transfer of patient information and transfer of patient care responsibilities from the OR team to the ICU team. Multiple studies suggest that these handoffs can expose patients to preventable harm, which can be avoided with standardization of the handoff. The Handoffs and Transitions in Critical Care (HATRICC; IRB #819726) study, started in 2014, developed and implemented a standardized OR to ICU handoff process in two Penn surgical ICUs (SICUs) that did not have a standardized handoff process.

Four clinicians (surgeon, anesthetist, ICU provider, and ICU nurse) from two teams (surgical and intensive care) usually take part in handoff communication. During the HATRICC study, the investigators evaluated handoff communication between the OR and ICU teams before and after implementation of the new standardized handoff process (the "HATRICC process") in multiple ways, using observations, interviews, focus groups, and surveys. The investigators demonstrated a 20% improvement in information exchange after implementation of the HATRICC standardized handoff process, a process tailored to meet the needs of the different clinicians participating in OR to ICU handoffs.

Prior studies have indicated short-term success in standardizing OR to ICU handoffs, but sustainability of these improvement interventions has been less well studied. Two studies have demonstrated sustained or improved information exchange following the institution of structured OR to ICU handoff processes, but the factors influencing sustainability remain to be elucidated.

The aims of this study are to:

  1. Ascertain determinants of OR-to-ICU handoff protocol adoption and use in 12 adult and pediatric ICUs in five health systems.
  2. Adapt handoff protocols using engineering approaches and select tailored implementation strategies with implementation mapping.
  3. Test the effectiveness of tailored, multifaceted, multilevel implementation strategies.
  4. Design and create a digital toolkit for other ICUs to identify implementation determinants, customize OR-to-ICU handoff protocol, and select appropriate implementation strategies.
03

Conditions studied

  • Patient Handoff
  • Healthcare Team
  • Communication
  • Patient Safety
  • Intensive Care Units

Browse trials for

Keywords

  • Implementation
  • Quality Improvement
  • Patient Safety
  • Handoffs
  • Intensive Care Unit
  • Postoperative Care
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for Clinicians:

  • Age ≥ 18 years
  • Cares for patients at any point in the surgical continuum of care, including pre-operative, intra-operative, or post-operative care, OR has administrative responsibilities relevant to patient care at the study hospitals
  • Fluency in English

Inclusion Criteria for Patients:

  • Patient admitted for inpatient care at the study hospitals and experiences a post-operative handoff from the operating room to the intensive care unit.

Exclusion Criteria for Clinicians:

  • Being a member of research staff

Exclusion Criteria for Patients:

  • (none)
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4,000 participants (actual)

Study arms

  • Experimental
    Customized Or to ICU handoff protocol

    Tailored implementation strategies will be used in 12 ICUs to facilitate the uptake and sustained use of a customized handoff protocol to be used by clinicians at the time of patient care transition from the operating room to the intensive care unit.

    Behavioral: Customized handoff

Interventions

  • BehavioralCustomized handoff

    A customized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.

06

What researchers measure

Primary outcomes

  1. Adherence to standardized handoff intervention (Fidelity) measured by number of handoff steps followed.

    Fidelity is defined as adherence to the standardized handoff intervention. Fidelity is a count of handoff steps followed, with scores ranging from 0 to 10. Fidelity will be measured by trained site-based observers. Field notes by trained observers will inform the interpretation of fidelity. Units of analysis: patient level (handoff level), ICU level.

    Time frame: This outcome will be measured at monthly intervals starting Year 1, Quarter 2 and continuing until the end of Year 5.

  2. New-onset organ failure

    Per-protocol handoffs enable clinicians to follow expected care practices and to anticipate and avoid postoperative deterioration.

    Time frame: This outcome will be measured at monthly intervals starting Year 1, Quarter 2 and continuing until the end of Year5

Secondary outcomes

  1. Perception among implementation stakeholders that a given treatment, service, practice, or innovation is agreeable, palatable, or satisfactory (Acceptability)

    Acceptability is defined as "the perception among implementation stakeholders that a given treatment, service, practice, or innovation is agreeable, palatable, or satisfactory." (Proctor et al, Adm Policy Ment Health (2011) 38:65-76). Acceptability will be measured using the Acceptability of Intervention Measure (AIM) developed by Weiner et al (Implement Sci. 2017;12(1):108; see Appendix). Interview and focus group transcripts and field notes will be analyzed to develop a more nuanced understanding of acceptability. Unit of analysis: individual (employed staff)

    Time frame: Baseline (Year 1); within 2months of implementation; within 2 months of beginning sustainment

  2. Perceived fit, relevance, or compatibility of the innovation in a practice setting or to address a particular issue (Appropriateness), measured by the Intervention Appropriateness Measure

    Appropriateness is defined as "the perceived fit, relevance, or compatibility of the innovation or evidence based practice for a given practice setting, provider, or consumer; and/or perceived fit of the innovation to address a particular issue or problem." (Proctor et al, Adm Policy Ment Health (2011) 38:65-76). Appropriateness will be measured using the Intervention Appropriateness Measure (IAM) developed by Weiner et al (Implement Sci. 2017;12(1):108; see Appendix). Interview and focus group transcripts and field notes will be analyzed to develop a more nuanced understanding of appropriateness. Unit of analysis: individual (employed staff)

    Time frame: Baseline (Year 1); within 2months of implementation; within 2 months of beginning sustainment

  3. Feasibility of treatment or innovation to be carried out in a practice setting, measured using the Feasibility of Intervention Measure.

    Feasibility is defined as "the extent to which a new treatment, or an innovation, can be successfully used or carried out within a given agency or setting." (Proctor et al, Adm Policy Ment Health (2011) 38:65-76). Feasibility will be measured using the Feasibility of Intervention Measure (FIM) developed by Weiner et al (Implement Sci. 2017;12(1):108; see Appendix). Interview and focus group transcripts and field notes will be analyzed to develop a more nuanced understanding of feasibility. Unit of analysis: individual (employed staff)

    Time frame: Baseline (Year 1); within 2months of implementation; within 2 months of beginning sustainment

  4. Fidelity over time (Sustainment)

    Sustainment is defined as fidelity over time. We define the sustainment phase as starting two years after implementation. Units of analysis: patient level (handoff level), ICU level.

    Time frame: This outcome will be measured at monthly intervals starting 2 years after implementation, up to 5 years.

  5. Monetary and non-monetary costs measured using the line item classification system

    We will conduct a retrospective cost analysis as described by Hoeft et al (Implementation Science 2019;14(1):37). We will use the line item classification system, in which accounting principles are used to calculate costs, and will attempt to include both monetary costs and non-monetary costs (e.g., opportunity costs). Activities undertaken only for research (e.g., interviews and focus groups) will not be included in this analysis. Field notes will be the primary data source for this outcome. Unit of analysis: ICU level.

    Time frame: This outcome will be measured within 2 months of implementation; within2 months of beginning sustainment

  6. Teamwork (effectiveness) measured using the Team Emergency Assessment Measure.

    Teamwork will be measured using a validated instrument, the Team Emergency Assessment Measure (TEAM) (Cooper et al, Resuscitation 2010;81(4):446-452). Unit of analysis: handoff team.

    Time frame: This outcome will be measured at quarterly intervals starting Year 1, Quarter 2 and continuing until the end of Year 5

  7. Clinician satisfaction measured at the individual level.

    Clinician satisfaction will be measured using a non-validated instrument adapted from the parent HATRICC study (see Appendix). Unit of analysis: individual.

    Time frame: This outcome will be measured annually from Years 1 to 5.

  8. Workload measured using the NASA Task Load Index.

    Workload is a measure of effectiveness and will be measured using the validated NASA Task Load Index.

    Time frame: This outcome will be measured at quarterly intervals starting Year 1, Quarter 2 and continuing until the end of Year 5.

  9. Completeness of information exchange (Information Omissions) measured using a structured observation form.

    Information omissions is a measure of the completeness of information exchange. It will be measured at the same time as fidelity using a structured observation form (see Appendix). Unit of analysis: patient level (handoff level).

    Time frame: This outcome will be measured at monthly intervals starting Year 1, Quarter 2 and continuing until the end of Year5

  10. Weighted average of the reliability-adjusted observed-to-expected ratios for component indicators of adverse events

    This is a composite measure defined by AHRQ as "the weighted average of the reliability-adjusted observed-to-expected ratios (indirect standardization of the smoothed rates) for the following component indicators: PSI 03 Pressure Ulcer Rate; PSI 06 Iatrogenic Pneumothorax Rate; PSI 07 Central Venous Catheter-Related Blood Stream Infection Rate; PSI 08 Postoperative Hip Fracture Rate; PSI 09 Perioperative Hemorrhage or Hematoma Rate; PSI 10 Postoperative Physiologic and Metabolic Derangement Rate; PSI 11 Postoperative Respiratory Failure Rate; PSI 12 Perioperative Pulmonary Embolism or Deep Vein Thrombosis Rate; PSI 13 Postoperative Sepsis Rate; PSI 14 Postoperative Wound Dehiscence Rate; PSI 15 Accidental Puncture or Laceration Rate." We note that some of the components of this measure overlap with our primary effectiveness outcome. Unit of analysis: ICU-level.

    Time frame: This outcome will be measured at quarterly intervals starting Year 1, Quarter 2 and continuing until the end of Year 5.

  11. AHRQ PSI 9: Perioperative hemorrhage or hematoma rate(effectiveness)

    This measure is one of the five components of the co-primary outcome of new-onset organ failure. It is defined by AHRQ as "perioperative hemorrhage or hematoma cases with control of perioperative hemorrhage, drainage of hematoma, or a miscellaneous hemorrhage- or hematoma-related procedure following surgery per 1,000 surgical discharges." AHRQ collects this information for patients aged 18 and older, but we will collect this outcome for pediatric patients in the two pediatric ICUs. Unit of analysis: ICU-level.

    Time frame: This outcome will be measured at monthly intervals starting Year 1, Quarter 2 and continuing until the end of Year 5

  12. AHRQ PSI 10: Postoperative physiologic or metabolic derangement rate (effectiveness)

    This measure is one of the five components of the co-primary outcome of new-onset organ failure. It is defined by AHRQ as "postoperative acute renal failure (secondary diagnosis) with dialysis per 1,000 elective surgical discharges." AHRQ collects this information for patients aged 18 and older, but we will collect this outcome for pediatric patients in the two pediatric ICUs. Unit of analysis: ICU-level.

    Time frame: This outcome will be measured at monthly intervals starting Year 1, Quarter 2 and continuing until the end of Year 5.

  13. AHRQ PSI 11: Postoperative respiratory failure rate (effectiveness)

    This measure is one of the five components of the co-primary outcome of new-onset organ failure. It is defined by AHRQ as "postoperative respiratory failure (secondary diagnosis), prolonged mechanical ventilation, or reintubation cases per 1,000 elective surgical discharges." AHRQ collects this information for patients aged 18 and older, but we will collect this outcome for pediatric patients in the two pediatric ICUs. Unit of analysis: ICU-level.

    Time frame: This outcome will be measured at monthly intervals starting Year 1, Quarter 2 and continuing until the end of Year 5

  14. AHRQ PSI 12: Perioperative pulmonary embolism or DVT rate (effectiveness)

    This measure is one of the five components of the co-primary outcome of new-onset organ failure. It is defined by AHRQ as "perioperative pulmonary embolism or deep vein thrombosis (secondary diagnosis) per 1,000 surgical discharges." AHRQ collects this information for patients aged 18 and older, but we will collect this outcome for pediatric patients in the two pediatric ICUs. Unit of analysis: ICU-level.

    Time frame: This outcome will be measured at monthly intervals starting Year 1, Quarter 2 and continuing until the end of Year 5

  15. AHRQ PSI 13: Post operative sepsis rate (effectiveness)

    This measure is one of the five components of the co-primary outcome of new-onset organ failure. It is defined by AHRQ as "postoperative sepsis cases (secondary diagnosis) per 1,000 elective surgical discharges." AHRQ collects this information for patients aged 18 and older, but we will collect this outcome for pediatric patients in the two pediatric ICUs. Unit of analysis: ICU-level.

    Time frame: This outcome will be measured at monthly intervals starting Year 1, Quarter 2 and continuing until the end of Year 5

  16. Professionalism of handoff team during handoff.

    Professionalism will be characterized qualitatively using field notes from trained observers. Unit of analysis: handoff team.

    Time frame: At quarterly intervals starting Year 1, Quarter 2 and continuing until the end of Year 5.

07

Study locations

5 sites
  • Johns Hopkins
    Baltimore, Maryland 21218, United States
  • Cooper Health
    Camden, New Jersey 08103, United States
  • Temple Health
    Philadelphia, Pennsylvania 19103, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
08

References and documents

Publications

  • Ashcraft LE, Watson MA, Vaughan C, Lee S, Yang S, Lane-Fall MB. Rapid and pragmatic implementation mapping for pre-implementation contextual analysis in multisite implementation trials. Front Health Serv. 2026 Jul 3;6:1782980. doi: 10.3389/frhs.2026.1782980. eCollection 2026. PubMed 42490896 ↗
  • Lane-Fall MB, Christakos A, Russell GC, Hose BZ, Dauer ED, Greilich PE, Hong Mershon B, Potestio CP, Pukenas EW, Kimberly JR, Stephens-Shields AJ, Trotta RL, Beidas RS, Bass EJ. Handoffs and transitions in critical care-understanding scalability: study protocol for a multicenter stepped wedge type 2 hybrid effectiveness-implementation trial. Implement Sci. 2021 Jun 15;16(1):63. doi: 10.1186/s13012-021-01131-1. PubMed 34130725 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Jul 2026, 63 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2020
First posted
Oct 1, 2020
StartActual
Apr 11, 2021
Primary completionActual
Jul 31, 2026
CompletionActual
Jul 31, 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Terminated PI Lane-Fall moved to a new institution. The original funding period ended and the grant was closed by the original institution before it was moved. We are working on reestablishing the IRB at the new institution to finish analysis procedures.
changed Oct 13, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42490896 ↗
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Enrolling by invitation→Terminated
    Why stopped PI Lane-Fall moved to a new institution. The original funding period ended and the grant was closed by the original institution before it was moved. We are working on reestablishing the IRB at the new institution to finish analysis procedures.
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42490896 ↗
    + 3 other changes: verification date, date precision and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04571749
Responsible party
Sponsor
First posted
Oct 1, 2020
Start date
Apr 11, 2021
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026
Last update
Oct 13, 2026

Study contacts

Meghan B Lane-Fall, MD, MSHP
principal investigator · Columbia University Vagelos College of Physicians and Surgeons

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion